FDA Approves AbbVie's JUVMO (tavapadon) for Parkinson's Disease

The U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets, developed by AbbVie, as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease. This approval offers a new approach to motor symptom control for patients, supported by positive results from the Phase 3 TEMPO clinical trial program.